Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610473 | 0.83 | HCRTR1 (0.43) | HCRTR1HCRTR2KCNH2KDM1AOPRL1 | |
| SCHEMBL2610468 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2KCNH2KDM1AOPRL1 | |
| SCHEMBL2610476 | 0.80 | HCRTR1 (0.40) | HCRTR1HCRTR2KCNH2KDM1AOPRL1 | |
| SCHEMBL15161946 | 0.79 | HCRTR1 (0.43) | HCRTR1HCRTR2KCNH2KDM1AOPRL1 | |
| SCHEMBL2610469 | 0.75 | HCRTR1 (0.36) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL24533938 | 0.71 | HCRTR1 (0.62) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL22666392 | 0.71 | HCRTR1 (0.62) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2116979 | 0.71 | HCRTR1 (0.62) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2116844 | 0.69 | HCRTR1 (0.51) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL15161960 | 0.69 | HCRTR1 (0.51) | HCRTR1HCRTR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885KCNH2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.